San Diego, California--(Newsfile Corp. - September 15, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies for the treatment of kidney diseases.The complaint alleges that Unicycive failed t ...

Unicycive Therapeutics (NasdaqCM:UNCY) FY Conference September 15, 2026 11:00 AM ET Company ParticipantsShalabh Gupta - Founder, Chairman, and CEOConference Call ParticipantsRamesh Kumar - AnalystRamesh KumarUnicycive is pursuing a 505(b)(2) pathway with composition of matter exclusivity until 2031. on June 30th of this year, the FDA issued a second CRL on the resubmitted NDA, tied entirely to previously identified third-party manufacturing deficiencies, and no concerns at all regarding the clinical efficac ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - September 1 ...